The utility of Bayesian predictive probabilities for interim monitoring of clinical trials
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Bayesian predictive probabilities can be used for interim monitoring of clinical trials to estimate the probability of observing a statistically significant treatment effect if the trial were to continue to its predefined maximum sample size. Purpose: We explore settings in which Bayesian predictive probabilities are advantageous for interim monitoring compared to Bayesian posterior probabilities, p-values, conditional power, or group sequential methods. Results: For interim analyses that address prediction hypotheses, such as futility monitoring and efficacy monitoring with lagged outcomes, only predictive probabilities properly account for the amount of data remaining to be observed in a clinical trial and have the flexibility to incorporate additional information via auxiliary variables. Limitations: Computational burdens limit the feasibility of predictive probabilities in many clinical trial settings. The specification of prior distributions brings additional challenges for regulatory approval. Conclusions: The use of Bayesian predictive probabilities enables the choice of logical interim stopping rules that closely align with the clinical decision-making process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 2×
“Additionally, frequentist approaches, such as Simon’s two-stage design [1,2], which minimize expected sample size for single-arm studies with a single interim analysis, are difficult to use when the number of patients accrued is not fixed [44].”
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Group sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831 · cited 2×
“Phase III designs typically use group sequential designs with alpha and beta-spending functions, such as O’Brien and Fleming [3] and Pocock [4]; see DeMets [5], and Thall and Simon [6]”
Wilber, D. J., Pappone, C., Neuzil, P., De Paola, A., Marchlinski, F., Natale, A., Macle, L., Daoud, E. G., Calkins, H., Hall, B., et al. (2010) · JAMA · doi:10.1001/jama.2009.2029 · Cited by 1,170 · cited 1×
“They are most often used to predict trial success at a final pre-determined sample size, but can also be used to predict trial success based on an interim sample size with extended follow-up [33-35].”
Bayesian approaches to randomized trials
Spiegelhalter, D. J., Freedman, L. S., & Parmar, M. K. B. (1994) · Journal of the Royal Statistical Society. Series A (Statistics in Society) · doi:10.2307/2983527 · Cited by 720
Cited by
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Woodcock, J., & LaVange, L. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510062 · Cited by 1,020
Adaptive platform trials: definition, design, conduct and reporting considerations
Coalition, T. A. P. T. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0034-3 · Cited by 412
The Platform Trial: An Efficient Strategy for Evaluating Multiple Treatments
Berry, S. M., Connor, J. T., & Lewis, R. J. (2015) · JAMA · doi:10.1001/jama.2015.2316 · Cited by 377
Self-citationEfficiencies of platform clinical trials: A vision of the future
Saville, B. R., & Berry, S. M. (2016) · Clinical Trials · doi:10.1177/1740774515626362 · Cited by 315
Self-citationCriner, G. J., Delage, A., Voelker, K., Hogarth, D. K., Majid, A., Zgoda, M., Lazarus, D. R., Casal, R., Benzaquen, S. B., Holladay, R. C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0383oc · Cited by 182
“Using a Bayesian adaptive design (22, 23), two interim analyses of sample size adequacy were conducted when 100 and 160 participants were enrolled, at which time the predictive probability of eventual success was calculated.”
Method
Metadata
- Authors
- Saville, B. R., Connor, J. T., Ayers, G. D., & Alvarez, J.
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2014-05-28
- Volume
- 11
- Issue
- 4
- Pages
- 485-493
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W1969100385
- Cited by
- 153
- References
- 5
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. https://app.cochat.ai/papers/10.1177/1740774514531352
- The paper
- Saville, B. R., Connor, J. T., Ayers, G. D., & Alvarez, J. (2014). The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clinical Trials. https://doi.org/10.1177/1740774514531352
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.